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Recent studies indicate that certain key molecules that are vital for various developmental processes, such as Wnt, Shh, and Notch, cause
cancer when dysregulated. PTEN, a tumor suppressor that antagonizes the PI3 kinase pathway, is the newest one on the list. The biological
function of PTEN is evolutionarily conserved from C. elegans to humans, and the PTEN-controlled signaling pathway regulates cellular
processes crucial for normal development, including cell proliferation, soma growth, cell death, and cell migration. In this review, we will
focus on the function of PTEN in murine development and its role in regulating stem cell self-renewal and proliferation. We will summarize
the organomegaly phenotypes associated with Pten tissue-specific deletion and discuss how PTEN controls organ size, a fundamental aspect
of development. Last, we will review the role of PTEN in hormone-dependent, adult-onset mammary and prostate gland development.
D 2004 Elsevier Inc. All rights reserved.
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Lloyd and Dennis (1962) published the first case report
on a brare, familial, developmental diseaseQ called
bCowden’s diseaseQ, after the family name of the proposita.
Patients with Cowden’s disease suffer from hamartomas
(benign growths) in multiple organs with a tendency of
malignant transformation. In 1997, three research laborato-
ries independently cloned a tumor suppressor gene located
on human chromosome 10q23 (Li and Sun, 1997; Li et al.,
1997; Steck et al., 1997). Sequence analysis indicated that
this gene encodes a phosphatase and shares a large region of
homology to tensin and auxilin. This tumor suppressor gene
was therefore named PTEN for phosphatase and tensin
homolog deleted on chromosome 10 (or MMAC1/TEP1). In
the same year, the link between Cowden’s disease and
PTEN mutations was formally established (Liaw et al.,
1997; Nelen et al., 1997). Many studies using either primary
tumor tissues or established tumor cell lines demonstrated
high frequencies of PTEN mutation/deletion in various0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2004.06.008
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E-mail address: hwu@mednet.ucla.edu (H. Wu).human cancers, including brain, bladder, breast, prostate,
and endometrial cancers (Ali et al., 1999; Aveyard et al.,
1999; Dahia, 2000; Dreher et al., 2004; Li et al., 1997;
Rasheed et al., 1997), marking PTEN the second most
frequently mutated human tumor suppressor gene (Stokoe,
2001). PTEN mutation was also found to be responsible for
two other autosomal dominant tumor predisposition syn-
dromes, Bannayan–Zonana syndrome (BZS) and Lher-
mitte–Duclos disease (LDD) (Arch et al., 1997; Iida et al.,
1998; Koch et al., 1999; Marsh et al., 1999).
Deletion of Pten in mouse models revealed that PTEN is
critical for animal development. Pten null embryos die early
during embryogenesis (Di Cristofano et al., 1998; Podsy-
panina et al., 1999; Stambolic et al., 1998; Suzuki et al.,
1998) and thus much of our current knowledge regarding
the functions of PTEN in development is acquired from
animals with tissue-specific Pten deletion using the Cre-
loxP system. Because the physiological functions of PTEN
in individual mouse tissues have been reviewed recently by
Kishimoto et al. (2003), we will emphasize how PTEN-
controlled signaling pathways regulate key biological events
related to normal development, including stem cell self-
renewal and proliferation, cell differentiation and migration,273 (2004) 175–184
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genesis. Although this review will focus on the role of
PTEN in murine development, it is worth noting that PTEN-
and PTEN-controlled signaling pathways are evolutionary
conserved and play fundamental roles in Drosophila (Gao et
al., 2000; Huang et al., 1999) and C. elegans (Gil et al.,
1999; Mihaylova et al., 1999; Rouault et al., 1999)
development and chemotaxis response of Dictystelium
(Funamoto et al., 2002; Iijima and Devreotes, 2002).PTEN-controlled signaling pathways and development
Studies on the molecular mechanism of PTEN function
revealed that the signaling pathways controlled by the
PTEN tumor suppressor are vital for both cell growth and
animal development (Vivanco and Sawyers, 2002). PTEN
functions as a phosphatase with both lipid and protein
phosphatase activities in vitro (Li and Sun, 1997;
Maehama and Dixon, 1998; Myers et al., 1998). While
its in vivo protein phosphatase activity remains to be
further investigated, PTEN’s lipid phosphatase activity has
been demonstrated both in vitro and in vivo. As a lipid
phosphatase, PTEN dephosphorylates phosphotidylinosital-
3,4,5-triphosphate (PIP3), a product of phosphotidylinosi-
tal-3-kinase (PI3Kinase) (Maehama and Dixon, 1998;
Stambolic et al., 1998; Sun et al., 1999). By dephopshor-
ylating PIP3, PTEN inhibits the growth factor signals
transduced through PI3Kinase, thus has a broad impact on
cell growth, cell migration, cell death, and cell differ-
entiation, processes involved in normal development (Fig.
1). PTEN deficiency leads to accumulation of PIP3 that in
turn activates several signaling molecules including the
phosphotidylinositol-dependent kinases (PDKs), the serine/
threonine kinases AKT/PKB, S6 kinase, and mTOR, as
well as small GTPases Rac1 and Cdc42 (Anderson et al.,
1998; Liliental et al., 2000; Pene et al., 2002; Stiles et al.,
2002; Sun et al., 1999; Wu et al., 1998). Among these
downstream signaling molecules, AKT is the best charac-
terized one (Anderson et al., 1998; Sun et al., 1999; Wu
et al., 1998). A number of substrates have been identified
for AKT kinase, including proapoptotic factor BAD (Datta
et al., 1997; del Peso et al., 1997), caspase 3 and 9
(Cardone et al., 1998), metabolic enzyme glycogen
synthase kinase (Cross et al., 1995), key cell cycle
modulators MDM2 (Ashcroft et al., 2002; Zhou et al.,
2001b), p21 and p27 (Collado et al., 2000; Zhou et al.,
2001a), members of the forkhead transcription factor
family (FOXOs) (Biggs et al., 1999; Brunet et al., 1999;
Guo et al., 1999; Kops et al., 1999; Nakae et al., 1999;
Takaishi et al., 1999; Tang et al., 1999), and nuclear
receptors AR (Lin et al., 2001) and ER (Campbell et al.,
2001; Mita et al., 2003). Phosphorylation of these
molecules leads to changes in their subcellular local-
ization, activities, or half lives, which in turn controls cell
metabolism, cell death, cell cycle progression, and celldifferentiation (for review, see Vivanco and Sawyers,
2002).
The PTEN/PI3 kinase/AKT signaling pathway also
interacts with other signaling pathways known to be
essential for normal development, including the TGF-h/
Smad pathway and the Wnt/h-catenin pathway. TGF-h
regulates many cellular processes that are crucial in
normal development. PTEN, also called TEP1 for TGF-
h-regulated and epithelial cell-enriched phosphatase (Li
and Sun, 1997), is rapidly downregulated by TGF-h in
keratinocytes and pancreas (Ebert et al., 2002; Li and
Sun, 1997). Conversely, PI3 kinase/AKT phosphorylates
SMAD3, a receptor-regulated SMAD, and inhibits
SMAD3-dependent TGF-h signaling (Song et al., 2003).
Similar to the TGF-h pathway, the Wnt signaling
pathway is also conserved in various organisms from
worms to mammals, and plays important roles in
development, cellular proliferation, and differentiation.
In mammals, the Wnt signal transduction pathway is
involved in many differentiation events during embryonic
development (for review, see Polakis, 2000). Activation
of the Wnt downstream molecule h-catenin leads to
tumor formation of various origins (Polakis, 2000). The
cytosolic pool of h-catenin has a short half-life in the
absence of Wnt signaling. Its turnover is controlled by
the action of a multi-protein complex (for a review, see
(Kikuchi, 2000), including at least Axin, APC, PP2A,
GBP, and GSK-3h. GSK-3h kinase phosphorylates h-
catenin on specific serine and threonine residues at its N-
terminus, targeting it to ubiquitin-mediated degradation
(Munemitsu et al., 1996; Yost et al., 1996). AKT kinase
phosphorylates and inhibits GSK-3h, leading to h-catenin
nuclear translocation and activation (Pap and Cooper,
1998; Yost et al., 1996). In addition to the above
signaling pathways, recent studies have pointed out the
role of PTEN in regulating the expression of homeobox
genes, such as NKX3.1 (Wang et al., 2003) and hepatic
nuclear factors (Wolfrum et al., 2003). Taken together,
PTEN can modulate animal development by multiple
mechanisms.PTEN expression and function in early development
Pten expression can be detected as early as embryonic
stem cell stage, which is derived from embryonic day 3.5
blastocysts (Sun et al., 1999). In situ hybridization and
immunohistochemistry analyses indicate that Pten is
expressed in both extraembryonic and embryonic tissues
(Luukko et al., 1999; Podsypanina et al., 1999). Within the
embryo proper, Pten is expressed ubiquitously during the
early stage of embryonic development (E7–11) but
becomes more restricted in the later stage (E15–19) in
tissues and organs (Podsypanina et al., 1999). Pten is
highly expressed in the central nervous system, liver, heart,
skin, and gastrointestinal tract, similar to the expression
Fig. 1. Signaling pathways controlled by PTEN. PTEN is a phosphatase that inhibits the growth factor/PI3 kinase signaling. One of PTEN’s enzymatic
activities is to dephosphorylate PIP3, the product of PI3 kinase and a major cellular second messenger. By dephosphorylating PIP3, PTEN inhibits the activity
of several downstream molecules, of which, the most important one is AKT. Activation of AKT by growth factors leads to increased cell cycle progression,
suppressed cell death as well as increased translation.
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al., 2000). At the cellular level, PTEN is present in both
cytosol and nucleus (Freeman et al., 2003; Gimm et al.,
2000; Li and Sun, 1997). Our recent study indicates that
the subcellular localization of PTEN may be developmen-
tally regulated and differential nuclear and cytoplasmic
expression of PTEN may reflect its role during different
stages of development and cellular functions (Wang and
Wu, unpublished observations).
To study the biological functions of PTEN, independ-
ent groups have generated Pten mutant animals by
deleting different regions of the Pten locus (Di Cristofano
et al., 1998; Podsypanina et al., 1999; Suzuki et al.,
1998). Animals heterozygous for Pten developed nor-
mally but homozygotes died early during embryogenesis,
bearing different onsets and phenotypes. While all groups
agreed that PTEN are essential for normal embryonic
development, they reached different conclusions on the
exact embryonic function of PTEN. Di Cristofano et al.
(1998) could not recover null embryos post E7.5 and
observed differentiation defects in Pten/ ES cell-
derived embryoid bodies. Pten null ES cells also failed
to contribute to the formation of the chimeric organism.
Thus, they concluded that PTEN is required for the
differentiation and organization of three germ layers (DiCristofano et al., 1998); Suzuki et al. (1998) obtained
gastrulated null embryos at E7.5 with severely expanded
and abnormally patterned cephalic and caudal regions at
E8.5. Knockout embryos generated in our laboratory have
similar defects as reported by Suzuki et al. (Freeman and
Wu, unpublished observations). In addition, we found
that Pten null ES cells were able to contribute efficiently
to chimeric animals. These discrepancies could be due to
several mechanisms, including the nature of deletions
made by individual groups, the genetic background of the
mutant animals, as well as the specific assays conducted
(Bradley and Luo, 1998). Nevertheless, in light of the
ubiquitous expression nature of Pten gene during early
embryogenesis, one should not be surprised if Pten null
embryos are dead due to abnormal development of
multiple organs and tissues.PTEN regulates stem cell function
Development fulfills two major functions: it generates
cellular diversity and order within an individual, and it
assures the continuity of life from one generation to the
next. Stem cells play essential roles in both of the
aforementioned functions. Stem cells are generally defined
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lineage differentiation. Embryonic stem cells (ES) or
primordial germ cells (PGC or EG) derived from early
embryos are totipotent, which can give rise to every single
cell type in our body, including germ cells that are vital for
propagating genetic materials from one generation to the
next one. Somatic stem cells present in individual organs
or tissues, on the other hand, are generally regarded as
having more limited differentiation potentials than ES cells
and are responsible for normal organogenesis and tissue
repair throughout the life of an individual (Weissman et al.,
2001). Among many key molecules that are crucial for
normal development and tumorigenesis, Wnt, Shh, Notch,
as well as their controlled signaling pathways are known to
have important roles in regulating stem cell self-renewal,
proliferation, and differentiation (Reya et al., 2001).
Because Pten is highly expressed in ES cells, the functions
of PTEN in ES cells have been studied independently by
different groups. Di Cristofano et al. showed that Pten null
ES cells have enhanced anchorage-independent growth
property. However, under regular adherent conditions Pten
null ES cells behaved similar to WT controls in their
growth rate and cell cycle distribution (Di Cristofano et al.,
1998). Our studies, on the other hand, indicated that
Pten/ ES cells exhibited an increased growth rate under
normal growth condition and could proliferate and survive
even in the absence of serum. ES cells lacking PTEN
function also displayed advanced entry into S phase (Sun
et al., 1999). Importantly, deletion of Akt-1, the major Akt
family member in Pten null ES cells, completely reversed
the growth advantage phenotype seen in Pten/ cells
(Stiles et al., 2002), further supporting the essential role of
AKT in PTEN-controlled ES cell proliferation and
survival.
ES cells are a rather special type of stem cells because
they do not exhibit contact inhibition and will not enter G0
cell cycle arrest. In contrast, most somatic stem cells are
situated in a quiescent stage. The mechanisms controlling
stem cell G0–G1 transition, self-renewal, and proliferation
are poorly understood. By specifically deleting Pten in the
brain during mid-embryonic development, we generated
mutant mice in which the brain size as well as weight is
doubled, similar to macrocephaly found in humans with
inherited PTEN deletions/mutations (Groszer et al., 2001).
Further studies indicated that the enlarged brain results
from increased cell proliferation, decreased cell death, and
enlarged cell size. The histoarchitecture of the mutant
brain also appears abnormal. However, cell fate commit-
ments of the progenitors were largely undisturbed.
Because all neural cell types are derived from a common
stem cell, the neural stem cell, the abnormal phenotypes
observed in the mutant brain prompt us to study the neural
stem cell population. Our in vitro analysis indicates that
there are more stem cells in the mutant brain, and these
stem cells are undergoing more self-renewal divisions.
Moreover, PTEN-deficient neural stem/progenitor cellshave a greater proliferation capacity, which is due, at
least in part, to a shortened cell cycle time (Groszer et al.,
2001).
The role of PTEN in regulating stem cell self-renewal
and proliferation is further supported by the generation of
Pten null primordial germ cells (PGCs) (Kimura et al.,
2003; Moe-Behrens et al., 2003). To study the intracellular
signaling pathways that control PGC proliferation and
differentiation, Kimura et al. have generated mice with
PGC-specific deletion of the Pten gene. PGC-specific Pten
deletion resulted in impaired mitotic arrest and outgrowth
of cells with immature characters accompanied by bilateral
testicular teratoma formation. Interesting, Pten null PGCs
in culture have greater proliferative capacity, similar to
what we have observed in Pten null ES cells. They also
demonstrated enhanced pluripotent embryonic germ cell
colony formation from Pten null PGCs (Kimura et al.,
2003), providing additional proof for the role of PTEN in
regulating stem cell self-renewal.PTEN and cell migration, cell fate determination
Even though PTEN plays important roles in stem cell
self-renewal and proliferation, Pten deletion does not
change the overall cell differentiation program. Humans
with PTEN germline mutations develop hamartomas in
tissues derived from all three germ layers (Liaw et al.,
1997; Marsh et al., 1998; Nelen et al., 1997). These focal
hyperplastic or dysplastic lesions are formed by overgrowth
of tissue elements normally present at these sites, indicating
that PTEN-deficient cells in a variety of tissues remain
responsive to exogenous and endogenous differentiation
cues. Concordantly, it has been shown that PTEN is
dispensable for fate determination of forebrain cortical
(Groszer et al., 2001) and cerebellar (Marino et al., 2002)
progenitor cells in vivo and in vitro. Similarly, over-
expression of Akt or deletion of dPTEN in Drosophila did
not affect cell-fate determination either (Gao et al., 2000;
Huang et al., 1999; Verdu et al., 1999).
PTEN, on the other hand, does control cell migration. It
has been suggested that PTEN negatively regulates cell
migration by directly dephosphorylating p125FAK and
changing MAP kinase activity (Gu et al., 1999; Tamura
et al., 1998). However, we failed to detect hyperphosphor-
ylation of p125FAK or hyperactivation of MAP kinase in
Pten null tissue or cells. Instead, we observed that PTEN
negatively regulates MEF cell mobility by downregulation
of Rac-1 and Cdc-42, two small GTPase activities in vitro
(Liliental et al., 2000). In Dictyostelium, PTEN coordinates
G protein coupled signaling pathways during chemotaxis.
PTEN is localized opposite to the migration leading edge,
and deletion of PTEN leads to dramatically prolonged and
broadened PH domain relocation and actin polymerization
responses (Funamoto et al., 2002; Iijima and Devreotes,
2002). However, in tissues with multiple cell types, PTEN’s
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Pten+/ SVZ progenitor cells seem to migrate faster (Li et
al., 2002b), abnormal layering and morphological alter-
ations have been observed in Pten conditional deleted
brain, suggesting possible defects in cellular migration
(Backman et al., 2001; Marino et al., 2002). In En2-Cre+/;
Ptenlox/lox mice older than 3 weeks, Purkinje cells are
clustered above the forth ventricle without recognizable
orientation and do not migrate toward the cerebellar surface
(Marino et al., 2002). Moreover, clusters of cerebellar
granule cells, which failed to migrate inward, were found in
the molecular layer (Marino et al., 2002). Postmitotic
granule cells that express mature granule cell markers
showed a similar phenotype in GFAP-Cre+/; Ptenlox/lox
mice (Backman et al., 2001; Kwon et al., 2001). Therefore,
the authors concluded that these might indicate a defect in
granule cell migration rather than a persistence of the EGL
(Kwon et al., 2001). Whether the observed defects are due
to changes in cell intrinsic properties of granule cells or
caused by alterations in environmental cues requires further
investigation.PTEN negatively regulates cell and organ size
Size regulation is fundamental for developmental biology.
The size of a particular organ can be influenced by both
extrinsic and intrinsic factors. Recent evidence suggests that
insulin and IGF-1 may play critical roles in organ size
controls in both mammals and other multi-cellular organisms
(Beck et al., 1995; Bohni et al., 1999; Brogiolo et al., 2001;
McMullen et al., 2004; Petrik et al., 1999; Powell-Braxton et
al., 1993; Xu et al., 2002). Studies inDrosophila suggest that
the pathway responsible to insulin/IGF-1 signaling is the
determination factor for organ size control (Bohni et al.,
1999; Brogiolo et al., 2001; Goberdhan and Wilson, 2002).
Loss of dPten, the negative regulator of the insulin and IGF-1
signaling pathway, causes increased cell size, organ size, as
well as animal size (Bohni et al., 1999). Overexpression of
dPten, on the other hand, results in completely opposite
effects (Gao et al., 2000; Huang et al., 1999). Similarly, in
Pten conditional knockout mice, deletion of Pten bypasses
the organ size control and leads to organomegaly in liver,
brain, heart, prostate, and skin (Backman et al., 2001;
Crackower et al., 2002; Groszer et al., 2001; Kwon et al.,
2001; Li et al., 2002a; Stiles et al., 2002; Suzuki et al., 2003;
Wang et al., 2003).
Organ size control involves two processes: cell size
control and cell number regulation. Under normal conditions,
these two processes are reciprocally controlled to determine
organ size. This relationship is best illustrated in experiments
with salamanders. Tetraploid salamanders are composed only
half the number of cells that are seen in the diploid ones. The
tetraploid salamanders developed giant cells to compensate
for this lack of cell number (Frankhauser, 1945). Apparently,
PTEN controls both cell size and cell number checkpoints:PTEN regulates cell number by inhibiting cell cycle
progression and inducing apoptosis (Sun et al., 1999); PTEN
also controls translationmechanisms through its regulation of
mTOR/S6K signaling, thus influencing cell size (Groszer
et al., 2001; Kwon et al., 2003; Neshat et al., 2001).
PTENmay control cell number and cell size in a cell-type-
and cell differentiation status-dependent manner. Even
though Pten null ES cell, MEF cells, and thymocytes do
not show any apparent size control defect, Pten-deleted
neurons and prostatic epithelial cells are clearly larger than
theirWTcontrols (Backman et al., 2001; Groszer et al., 2001;
Kwon et al., 2001, 2003; Wang et al., 2003). Increased cell
proliferation is evidenced in undifferentiated Pten null ES
cells and neural stem cells (Groszer et al., 2001; Sun et al.,
1999), but not in differentiated neurons and MEFs (Backman
et al., 2001; Sun et al., 1999). Similarly, activated AKT may
differentially modulate cell size and cell number checkpoints.
Activation of AKT in the Drosophila imaginal disc and
mouse pancreatic h-cells leads to increased cell size and
compartment size, independent of cell proliferation (Tuttle et
al., 2001; Verdu et al., 1999). Overexpression of Akt in the
prostate epithelium, on the other hand, increases both cell
number and cell size (Majumder et al., 2003).PTEN in regulation of hormone responses
The development of sexual organs involves additional
regulation by hormones, such as androgen and estrogen. At
the onset of sexual maturity, these hormones stimulate the
proliferation, differentiation, and maturation of mammary,
endometric and prostate epithelium, resulting in significant
changes in their morphological appearances and functions.
Female patients with germline PTEN deletion suffer from
bilateral hypertrophy of the virginal breasts and early
malignant transformation (Lloyd and Dennis, 1962). How-
ever, the exact mechanisms of PTEN in controlling mammary
gland development are unclear. Conditional deletion of Pten
in the virgin mammary gland leads to hypersensitivity to
hormone stimulation, resulting in dramatically increased
ductal branching and BrdU incorporation (Li et al., 2002a).
The virgin mutant gland also contains many lobulo-alveolar
buds and expresses milk-specific proteins, which are
normally associated with hormonal stimulation during
pregnancy. Conversely, overexpression of Pten inhibits
differentiation of mammary tissues and resulted in dysfunc-
tional lactation (Dupont et al., 2002). ThePten null mammary
gland is also less sensitive to hormone withdrawal during
weaning as evidenced by decreased cell apoptosis and
impaired involution process. Recent studies suggest that
PI3Kinase/AKT can active estrogen receptor in the absence
of estrogen (Campbell et al., 2001). These results suggest that
PTEN is one of the important factors controlling the hormone
responsiveness of mammary epithelial cells during normal
mammary gland development and mammary gland cycling,
and provide a mechanistic explanation for the bilateral
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disease patients.
Similarly, deletion of Pten in prostate resulted in enlarged
prostate glands as early as postnatal 4 weeks, which is
partially due to increased cell proliferation and cell size of
Pten null prostate epithelium (Wang et al., 2003). Pten null
prostate cancer cells are also capable of proliferation in the
absence of androgen. Surprisingly, Pten null prostatic
epithelial cells are sensitive to androgen withdrawal and
die rapidly after castration even though AKT is hyper-
activated in these cells. Several recent studies suggest theFig. 2. The biological function of PTEN and its role in disease progression. In stem
also determines whether cells in G0 resting stage re-enter the cell cycle. This r
controlling whether normal stem cells is to become cancer stem cells. In postmitoti
cell proliferation and differentiation. Through regulating these processes, PTEN pla
as normal organ development.presence of cross talks between the PI3Kinase/AKT and AR
signaling pathways. Unfortunately, the effects in different
cell lines and from different laboratories often seem contra-
dictory, leading to confusion in the field as to whether
PI3Kinase/AKT exerts a positive or negative effect on AR
(Lin et al., 2002; Manin et al., 2002). For example, Manin et
al. (2002) have claimed that the PI3kinase/AKT pathway is
required for basal and dihydrotestosterone-induced AR
expression in prostate cell lines; whereas Lin et al. (2002)
have shown that AKT and Mdm2 form a complex with AR
and promote phosphorylation-dependent AR ubiquitination,/progenitor cells, PTEN acts to regulate not only G1/S and G2/M switch, but
ole of PTEN in regulating cell cycle re-entry maybe an important switch
c cells, PTEN plays a wide range of function regulating from metabolism to
ys a role in insulin resistance, organ size control, tumor development as well
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studies, by employing in vivo systems, may help clarify this
controversial observation.Perspectives
Studies from the last few years clearly established the
vital role of PTEN in regulating normal development and
physiology, and illustrated the detrimental effects of PTEN
dysregulation in tumorigenesis (Fig. 2). PTEN functions in
multiple tissues and organs, from early embryogenesis to
sexual organ development in adulthood. The role of PTEN
is best illustrated by its broad expression pattern and
abnormal phenotypes associated with animal models with
Pten tissue-specific deletion. PTEN regulates stem cell
self-renewal and proliferation without perturbing the fate
of cell differentiation. PTEN also controls organ size by
modulating the checkpoints of cell proliferation and soma
growth.
Several important issues raised by current studies are
worth further investigation. First, self-renewal is the
hallmark property of stem cells, but how PTEN controls
stem cell self-renewal remains unknown. Majority of
somatic stem cells are arrested at G0 until proper
stimulations trigger them to proliferate to generate more
stem cells and to repopulate the injured tissues. We have
observed hyperproliferation and enhanced self-renewal in
Pten null neuronal stem/progenitor cells, suggesting that
PTEN may modulate G0–G1 transition (Groszer et al.,
2001). Nuclear expression of PTEN varies throughout the
cell cycle with highest expression at G0–G1 phase and
lower levels in S phase (Ginn-Pease and Eng, 2003).
Together, these studies suggest nuclear PTEN may play a
more direct role in regulating cell cycle reentry. Further
study is necessary to elucidate the signaling pathways
involved. Second, whether PTEN has protein phosphatase
activity in vivo and the importance of such activity remain
to be determined. Sequence analysis suggests that PTEN
contains a sequence motif that is highly conserved among
members of the protein tyrosine phosphatase family (Li
and Sun, 1997; Li et al., 1997). Structurally, the PTEN
phosphatase domain is similar to protein phosphatase, but
its active site is large enough to accommodate lipid
substrates, for example, PIP3 (Lee et al., 1999). In vitro
analysis suggests that PTEN possesses phosphatase activity
on phosphotyrosyl-, phosphothreonyl-, and phosphoseryl-
containing substrates (Li and Sun, 1997; Myers et al.,
1998). Furthermore, FAK has been proposed as a possible
protein substrate of PTEN (Gu et al., 1999; Tamura et al.,
1998), although FAK phosphorylation status does not
change in Pten-deficient embryonic stem cells or fibro-
blasts (Liliental et al., 2000). It has also been shown that
PTEN-null mutation in Drosophila does more than just
affect the PI3kinase pathway (Gao et al., 2000; Huang et
al., 1999). Another interesting observation is that PTENcan dephosphorylate itself and PTEN’s protein phosphatase
activity is required for self-regulation (Raftopoulou et al.,
2004). So an attractive hypothesis is that PTEN may
regulate its own activity and the activity of various protein
substrates by controlling their phosphorylation and local-
ization. Third, maintaining proportional organ size is
fundamental to development. However, the mechanism
underlying organ size regulation remains poorly under-
stood. The enlarged organ and cell size phenotypes
observed in Pten tissue-specific-deleted animals may
provide a unique opportunity to address this fundamental
question.
Development and tumorigenesis are tightly linked, and
tumor formation may be viewed as abnormal development.
Signaling pathways critical for development processes could
cause cancer when dysregulated. Thus, studying how PTEN
regulates normal development may shed light on our
understanding of the molecular mechanisms that underlie
PTEN-controlled tumorigenesis and vice versa.Acknowledgments
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